Fibronectin 1 promotes migration and invasion of papillary thyroid cancer and predicts papillary thyroid cancer lymph node metastasis
- PMID: 28367057
- PMCID: PMC5370387
- DOI: 10.2147/OTT.S122009
Fibronectin 1 promotes migration and invasion of papillary thyroid cancer and predicts papillary thyroid cancer lymph node metastasis
Erratum in
-
Erratum: Fibronectin 1 promotes migration and invasion of papillary thyroid cancer and predicts papillary thyroid cancer lymph node metastasis [Corrigendum].Onco Targets Ther. 2017 May 29;10:2737-2738. doi: 10.2147/OTT.S139132. eCollection 2017. Onco Targets Ther. 2017. PMID: 28603422 Free PMC article.
Abstract
Lymph node metastasis (LNM) is common in papillary thyroid cancer (PTC), and is an indicator of recurrence. The detailed molecular mechanism of LNM in PTC has not been well described. This study aimed to investigate the role of fibronectin 1 in PTC LNM and its clinical relevance. The expression of fibronectin 1 was confirmed in PTC tissues and cell lines. A correlation analysis was conducted and a receiver-operating characteristic curve obtained. The effect of fibronectin 1 on the proliferation of PTC cell lines was performed using a colony-formation assay and Cell Counting Kit 8. Cell-cycle analysis was performed with a flow-cytometry assay. Migration and invasion ability were evaluated by transwell and wound-healing assays. Fibronectin 1 was overexpressed in metastasized PTC. Overexpressed fibronectin 1 was positively correlated with PTC LNM. Receiver-operating characteristic analysis showed that the diagnostic accuracy of fibronectin 1 was 81.1%, with sensitivity of 80% and specificity of 82%. Overexpression of fibronectin 1 promoted proliferation, migration, and invasion in PTC. Fibronectin 1 plays a critical role in PTC metastasis by modulating the proliferation, migration, and invasion ability of PTC cells, and it is a valuable diagnostic biomarker for predicting PTC LNM.
Keywords: diagnostic biomarker; fibronectin 1; lymph node metastasis; papillary thyroid cancer.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Figures
Similar articles
-
MiR-324-5p assists ultrasonography in predicting lymph node metastasis of unifocal papillary thyroid microcarcinoma without extracapsular spread.Oncotarget. 2017 Jul 31;8(48):83802-83816. doi: 10.18632/oncotarget.19717. eCollection 2017 Oct 13. Oncotarget. 2017. PMID: 29137384 Free PMC article.
-
MKL1 overexpression predicts poor prognosis in patients with papillary thyroid cancer and promotes nodal metastasis.J Cell Sci. 2019 Aug 22;132(16):jcs231399. doi: 10.1242/jcs.231399. J Cell Sci. 2019. PMID: 31363007
-
Plasma Exosomal miR-146b-5p and miR-222-3p are Potential Biomarkers for Lymph Node Metastasis in Papillary Thyroid Carcinomas.Onco Targets Ther. 2020 Feb 13;13:1311-1319. doi: 10.2147/OTT.S231361. eCollection 2020. Onco Targets Ther. 2020. PMID: 32103998 Free PMC article.
-
MicroRNAs and Lymph Node Metastasis in Papillary Thyroid Cancers.Asian Pac J Cancer Prev. 2016;17(1):25-35. doi: 10.7314/apjcp.2016.17.1.25. Asian Pac J Cancer Prev. 2016. PMID: 26838219 Review.
-
Radiologist versus Non-Radiologist Detection of Lymph Node Metastasis in Papillary Thyroid Carcinoma by Ultrasound: A Meta-Analysis.Biomedicines. 2022 Oct 14;10(10):2575. doi: 10.3390/biomedicines10102575. Biomedicines. 2022. PMID: 36289838 Free PMC article. Review.
Cited by
-
Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids.Oncogene. 2024 Jan;43(3):155-170. doi: 10.1038/s41388-023-02889-y. Epub 2023 Nov 20. Oncogene. 2024. PMID: 37985676 Free PMC article.
-
SIK1 suppresses colorectal cancer metastasis and chemoresistance via the TGF-β signaling pathway.J Cancer. 2023 Aug 6;14(13):2455-2467. doi: 10.7150/jca.83708. eCollection 2023. J Cancer. 2023. PMID: 37670972 Free PMC article.
-
Proteomic Alteration in the Progression of Multiple Myeloma: A Comprehensive Review.Diagnostics (Basel). 2023 Jul 10;13(14):2328. doi: 10.3390/diagnostics13142328. Diagnostics (Basel). 2023. PMID: 37510072 Free PMC article. Review.
-
Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2.Mol Cancer Res. 2023 Sep 1;21(9):867-880. doi: 10.1158/1541-7786.MCR-22-1031. Mol Cancer Res. 2023. PMID: 37219859 Free PMC article.
-
Expression of miR-31-5p affects growth, migration and invasiveness of papillary thyroid cancer cells.Endocrine. 2023 Mar;79(3):517-526. doi: 10.1007/s12020-022-03267-6. Epub 2022 Dec 7. Endocrine. 2023. PMID: 36474133
References
-
- Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer. 1998;83(12):2638–2648. - PubMed
-
- Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer. 2006;106(3):524–531. - PubMed
-
- Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery. 2008;144(6):1070–1078. - PubMed
-
- Shindo M, Wu JC, Park EE, Tanzella F. The importance of central compartment elective lymph node excision in the staging and treatment of papillary thyroid cancer. Arch Otolaryngol Head Neck Surg. 2006;132(6):650–654. - PubMed
-
- Caron NR, Clark OH. Papillary thyroid cancer: surgical management of lymph node metastases. Curr Treat Options Oncol. 2005;6(4):311–322. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
